You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Dermatology
On demand events
Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?
Highlights from the ADVENT educational symposium at EADV 2024 where Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.
MD, PhD
Marjolein de Bruin-Weller +2 more
On demand materials
Learning objectives
- Review the role of type 2 inflammation, including the roles of IL-4 and IL-13, both locally and systemically in the pathophysiology of AD
- Explore the potential for disease modification, including the importance of early intervention, in patients with AD
- Highlight the latest real-world data regarding sustained disease control and disease modification in patients with AD treated with advanced systemic therapies
Description
In this ADVENT symposium at the EADV 2024 conference in Amsterdam, Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD, and the potential benefits of early intervention with regard to disease modification. Recent real-world data on the use of advanced systemic treatments for patients with AD was also presented.
Tags
MAT-GLB-2406718 - 3.0 - 02/2025
About these experts
